Navigation Links
Puma Biotechnology Announces Positive PB272 (Neratinib) Phase II Data at CTRC-AACR San Antonio Breast Cancer Symposium
Date:12/9/2011

a median of 3 prior cytotoxic regimens (range 1-12 prior regimens).  Patients in the HER2+ cohort of the trial received a median of 2 prior trastuzumab containing regimens (range 1-9 prior regimens).  Patients were administered PB272 at a dose of 240 mg per day in combination with temsirolimus given at a dose of 8 mg weekly.

The results of the study presented showed that the combination of PB272 and temsirolimus had acceptable tolerability.  The most frequently observed severe adverse events for the 20 patients evaluable for safety were grade 3 diarrhea (10% of patients), grade 3 hyperglycemia (5%), mucositis (5%), leukopenia (5%), and fatigue (5%). The efficacy results from the trial showed that for the 15 patients with HER2+ disease, 9 (60%) patients experienced a partial response and 1 (7%) patient experienced stable disease for greater than 6 months, which translates to a clinical benefit rate of 67%.  Patients who experienced a partial response to the combination of neratinib plus temsirolimus demonstrated a maximum change in the size of their target lesions of between 33% and 83%.  None of the 5 patients with triple negative breast cancer demonstrated a partial response or stable disease for greater than 6 months.

Alan H. Auerbach, Chief Executive Officer and President of Puma Biotechnology, said, "We are pleased with the PB272 data that has been presented at the San Antonio Breast Cancer Symposium.  The combination of PB272 given in combination with capecitabine shows strong evidence of antitumor activity in second and third line HER2+ metastatic patients, which we believe could position the drug well compared to other agents currently used to treat second and third line disease.  In addition, the data on the combination of PB272 in combination with temsirolimus demonstrates intriguing antitumor activity in a heavily pretreated population.  We look forward to continuing to study both of these combination
'/>"/>

SOURCE Puma Biotechnology, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. The European Union Signs Grant Contract to Fund a 2 Million Euro Biotechnology Research Project Led by Hadassah College Jerusalem
2. Animal Biotechnology - Technologies, Markets and Companies
3. Puma Biotechnology Announces Completion of Private Placement
4. HUYA Bioscience International Builds Long-Term Relationship with Shenzhen Polytechnic School of Applied Chemistry and Biotechnology
5. Congressman Eric Cantor and Health Diagnostic Laboratory, Inc. Discuss Job Growth at Virginia BioTechnology Research Park
6. Industrial Biotechnology China News 1109 - Annual Subscription
7. Nanobiotechnology: Applications and Global Markets
8. Californias Industrial Biotechnology Workforce: Creating Jobs and Leading Innovation
9. Global Biotechnology Instrumentation Industry
10. Separation Systems for Commercial Biotechnology
11. TWi Biotechnology Successfully Completes Patient Recruitment for Phase IIb Trial of AC-201 for the Treatment of Type II Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... 2015 AACC welcomed thousands of medical ... Annual Meeting & Clinical Lab Expo in ... meeting showcased revolutionary advancements in clinical testing technology ... providers to diagnose patients quickly and accurately and ... As of Wednesday, July 29, more ...
(Date:7/30/2015)... Texas (PRWEB) , ... July 30, 2015 , ... The ... and in-depth study on the current state of the global Propanol market with a ... Sinopec, CNPC, BASF, Eastman, Dow, Carboclor, Mitsui Chemicals, Oxea, ISU Chemical, Sanofi, Royal Dutch ...
(Date:7/30/2015)... 2015   Aratana Therapeutics, Inc . (NASDAQ: ... on the licensing, development and commercialization of innovative ... its strategic partner VetStem Biopharma, Inc. has shared ... AT-016, an adipose-derived allogeneic stem cell product exclusively ... pain in dogs. The double-blinded, multi-site, ...
(Date:7/30/2015)... 2015 Ascendis Pharma A/S (Nasdaq: ... innovative TransCon technology to address significant unmet medical ... six-month Phase 2 study to evaluate the safety ... 53 treatment-naïve, pre-pubertal children with growth hormone deficiency, ... with the top-line results from our Phase 2 ...
Breaking Biology Technology:Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 2Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 3Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 4Global Propanol Market Technical Data and Manufacturing Analysis 2020 2Global Propanol Market Technical Data and Manufacturing Analysis 2020 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 2Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 4Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7
... discovery that low-intensity, pulsed ultrasound can be used ... for engineering rapid-response medical devices. The team that ... an assistant professor with the Virginia Tech Carilion ... detailing this approach, which may one day lead ...
... Sept. 8, 2011 Enterologics, Inc  ( ... acquisition of The BioBalance Corporation and its subsidiary BioBalance ... this purchase Enterologics acquired its first probiotic biotherapeutic product, ... coli M17 has an active Investigational New Drug ...
... Seeds, an investment firm dedicated to achieving above market ... announced today that it has opened an office at ... support the growing number of investments the firm has ... its first Pittsburgh investment in 2006 in Redpath Pathologies, ...
Cached Biology Technology:Neuroscientists produce guide for ultrasound use to treat brain disorders in clinical emergencies 2Neuroscientists produce guide for ultrasound use to treat brain disorders in clinical emergencies 3Enterologics Completes Acquisition of BioBalance Corp and Probiotic Product From New York Health Care, Inc 2Enterologics Completes Acquisition of BioBalance Corp and Probiotic Product From New York Health Care, Inc 3Enterologics Completes Acquisition of BioBalance Corp and Probiotic Product From New York Health Care, Inc 4Golden Seeds Opens Office in PLSG Incubator 2Golden Seeds Opens Office in PLSG Incubator 3
(Date:7/31/2015)... Chine, 31 juillet 2015 La 10e ... ) sera organisée par le BGI du 22 ... en Chine. La conférence ... inauguration en 2006, l,ICG est devenue l,une des ... domaine des « omiques » et c,est aussi la plus ...
(Date:7/30/2015)... , July 30, 2015 Cellecta, ... for gene function analysis and biomarker discovery, announced ... (sgRNA) Knockout Library targeting all human protein coding ... permanently "knock out" a gene,s function. Cellecta,s new ... high throughput screening tool so that researchers can ...
(Date:7/21/2015)... -- Today, ZTE announced its Android smartphone Axon, featuring ... revenues in 2015 that relate to sales of FPC1025 for this ... 2,200 MSEK for 2015. Jörgen Lantto, CEO of FPC, ... China and we are proud that ... Axon , its first ...
Breaking Biology News(10 mins):La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 2La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 3CELLECTA, INC. Announces Launch of Human Whole Genome CRISPR Knockout Library 2FPC's Touch Fingerprint Sensor FPC1025 in ZTE's Smartphone Axon 2
... preference for speech through in-utero eavesdropping, or is their ... test, but one that's central to understanding the origins ... a McGill University psychologist believes she's separated out the ... results, says Dr. Athena Vouloumanos, point to a genetic ...
... University of Pennsylvania School of Medicine discovered that a ... internal molecular clock in mammals. What's more, this molecule ... light on circadian rhythm disorders, including bipolar disorder. The ... metabolism, are reported in this week's issue of Science. ...
... Scientists supported by the National Institute of Allergy and ... Health (NIH), have identified a defect in the immune ... that puts them at risk of developing serious complications ... Ph.D., of the National Jewish Medical and Research Center ...
Cached Biology News:Born with a love of speech 2Born with a love of speech 3Clock molecule's sensitivity to lithium sheds light on bipolar disorder 2Defective immune system response to smallpox vaccine detailed in new study 2Defective immune system response to smallpox vaccine detailed in new study 3
... The H2OBIT™ is a fully licensed, high throughput, ... processing of up to 24 microplates. This equates ... plates. A robotic arm rapidly transfers ... resulting in temperature ramping times that are considerably ...
... licensed, high throughput, water bath thermal cycler capable ... microplates. This equates to 9,216 reactions per run ... rapidly transfers a basket of plates between three ... are considerably faster than those of peltier block ...
... is a 27kDa periplasmic enzyme from E. ... to cyclic nucleotide monophosphate (NMP) intermediates. Slower ... intermediates to 3-NMPs (1). RNase ONE Ribonuclease ... that can cleave a phosophodiester bond between ...
... Dideoxycytidine is a cytidine analog that has been ... Immunogen: Chemical / Small Molecule ... specificity of the ddC antiserum was determined by ... to moles of ddC analog at the 50% ...
Biology Products: